RDC Stock Overview
Operates in online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Redcare Pharmacy NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €121.10 |
| 52 Week High | €171.40 |
| 52 Week Low | €95.60 |
| Beta | 1.26 |
| 1 Month Change | -10.23% |
| 3 Month Change | 7.26% |
| 1 Year Change | -12.69% |
| 3 Year Change | 53.02% |
| 5 Year Change | 75.25% |
| Change since IPO | 326.41% |
Recent News & Updates
Recent updates
Redcare Pharmacy NV (ETR:RDC) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 14
Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
Feb 27
eRx Surge And International Expansion Poised To Elevate Revenue And Profit Margins
Dec 30 Rapid expansion in new markets and tech-driven efficiencies suggest future revenue growth and improved profit margins.Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt
Nov 11Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?
Apr 21Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?
Apr 07Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues
Mar 25Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt
Feb 13Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S
Dec 24Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?
Dec 06Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?
Sep 07Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching
Aug 02Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price
Jul 17Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher
May 28Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt
May 11We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt
Jan 10Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?
Sep 25Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?
Jun 08Shareholder Returns
| RDC | DE Consumer Retailing | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -1.1% | -0.8% |
| 1Y | -12.7% | -3.9% | 2.3% |
Return vs Industry: RDC underperformed the German Consumer Retailing industry which returned -3.9% over the past year.
Return vs Market: RDC underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| RDC volatility | |
|---|---|
| RDC Average Weekly Movement | 9.0% |
| Consumer Retailing Industry Average Movement | 9.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 3.0% |
Stable Share Price: RDC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: RDC's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,827 | Olaf Heinrich | www.redcare-pharmacy.com |
Redcare Pharmacy NV operates in online pharmacy business in the Netherlands, Germany, Italy, Belgium, Switzerland, Austria, and France. It provides prescription and non-prescription over-the-counter pharmaceuticals, beauty and personal care products, and food supplements. The company was formerly known as Shop Apotheke Europe N.V. and changed its name to Redcare Pharmacy NV in June 2023.
Redcare Pharmacy NV Fundamentals Summary
| RDC fundamental statistics | |
|---|---|
| Market cap | €2.49b |
| Earnings (TTM) | -€45.46m |
| Revenue (TTM) | €2.37b |
1.1x
P/S Ratio-54.8x
P/E RatioIs RDC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RDC income statement (TTM) | |
|---|---|
| Revenue | €2.37b |
| Cost of Revenue | €1.82b |
| Gross Profit | €545.78m |
| Other Expenses | €591.24m |
| Earnings | -€45.46m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 06, 2025
| Earnings per share (EPS) | -2.21 |
| Gross Margin | 23.02% |
| Net Profit Margin | -1.92% |
| Debt/Equity Ratio | 41.3% |
How did RDC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/13 02:51 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Redcare Pharmacy NV is covered by 23 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Schwarz | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Otto Sieber | Barclays |